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LETTER TO THE EDITOR
Response to the letter from Drs Gold and Osband
Sir - We believe, like Drs Gold and Osband, that application
of CD45RO+CD4+ helper/killer cells to adoptive immuno-
therapy has many advantages for the potentiation of host
antitumour immunity. In previous papers (Nishimura et al.,
1991; 1992a,b; Nakamura et al., 1992) we initially developed
a large-scale culture system of pure human CR45RO+CD4+
T cells. We intend to use these CD4+ T cells for new trials of
adoptive immunotherapy, termed 'helper/killer therapy', in
combination with other kinds of killer cells (CD8+T or 76T)
and bispecific antibody (BSAb). Recent results have demon-
strated that introduction of local help by gene technology
resulted in the rejection of tumour cells of low immuno-
genicity (Fearon et al., 1990). Therefore, we believe that the
targeting of both CD4+ helper T cells and CD8+ T cells
using BSAb may facilitate the activation of antitumour
immunity at the local site of a tumour.
In the letter from Drs Gold and Osband, they claim that
their developed autolymphocyte therapy (ALT) is adoptive
tumour immunotherapy based upon the infusion of CD4+
CD45RO+ T cells activated with OKT3 and OKT3-stimu-
lated conditioned medium (T3CS). However, we cannot find
any evidence that they used CD4+CD45RO+ enriched T cell
populations for ALT. As described in their own paper
(Osband et al., 1990), the cells used for ALT consisted of
49.6% T cells and 51.4% other non-T cell populations. T
cells consisted of 45.6% CD4+ T cells and 18.4% CD8+ T
cells. Furthermore, activation of peripheral blood lym-
phocytes, which contained 26.7% CD4+CD45RO+2H4- T
cells, with OKT3 mAb and T3CS did not cause preferential
growth of the CD4+CD45RO+ (2H4-) T cell population
(24.2%). As described in their basic study (Celis et al., 1991)
and other results (Panzer et al., 1990), it was demonstrated
that the activation ofpurified CD4+ T cells with IL-1 or IL-1
containing T3CS resulted in the preferential growth of CD4+
CD45RO+ T cells. Therefore, the activation of isolated
CD4+ T cells with OKT3 mAb plus T3CS may improve the
yield of CD4+CD45RO+ T cells and may therefore confer
benefits for the therapeutic effect of ALT. In summary, our
answer to their first question is that we can agree the work-
ing hypothesis of ALT using CD4+CD45RO+ T cells, but we
cannot find any evidence from their data that unseparated
PBL are sufficient to induce preferential growth of CD4+
CD45RO+ T cells useful for adoptive tumour immuno-
therapy.
It is very interesting results that a certain threshold dose of
infused lymphocytes was critical for the therapeutic effect of
adoptive immunotherapy (Ross & Osband, 1989). They claim
that the suppressive effect of a large number of cells
(12-15 x 106 cells/KG/infusion) might be derived from the
CD4+CD45RO+ T cells which may cause an 'anti-idiotypic'
reaction with concomitant generation of suppressor cells.
This might be true if they use pure CD4+CD45RO+ T cells
for ALT. As described above, however, they used hetero-
geneous cell population which contained only 24.6% CD4+
CD45RO+ T cells. Therefore, it is not necessary to speculate
that infusion of a large number of CD4+ T cells might
suppress antitumour activity. They cannot exclude the pos-
sibility that classical CD8+ suppressor T cells showed in vivo
suppressive activity. Nevertheless, their results provide
important information concerning the number of cells used
for adoptive immunotherapy. The aims of ALT and helper/
killer therapy seem to be different. The aim of the former is a
potentiation of host antitumour immunity by systemic adop-
tive transfer. The aim of the latter is the targeting ofCD4+ T
cells and CD8+ T cells into the tumour tissues via the
tumour-feeding artery in combination with BSAb. In the case
of systemic administration, a small number of CD4+ T cells
might be sufficient for immunoregulatory action in vivo. In
contrast, large numbers of CD4+ T cells with CD8+ killer T
cells may be necessary for BSAb-dependent induction of IL-2
production and tumour eradication at the local sites because
tumour cells produce immunosuppressive factors.
In conclusion, we believe that separation of CD4+ T cells
from PBL before culture is essential for selective growth of
CD4+CD45RO+ T cells and that a large number of CD4+ T
cells may be necessary for the augmentation of local effects at
local sites of tumour involvement. We hope that Drs Gold
and Osband will demonstrate improved therapeutic effects of
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